644 related articles for article (PubMed ID: 33400075)
1. Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance.
Roy Burman D; Das S; Das C; Bhattacharya R
Mol Biol Rep; 2021 Jan; 48(1):897-914. PubMed ID: 33400075
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal splice isoform of CD44 (CD44s) promotes EMT/invasion and imparts stem-like properties to ovarian cancer cells.
Bhattacharya R; Mitra T; Ray Chaudhuri S; Roy SS
J Cell Biochem; 2018 Apr; 119(4):3373-3383. PubMed ID: 29130517
[TBL] [Abstract][Full Text] [Related]
3. Direct Regulation of Alternative Splicing by SMAD3 through PCBP1 Is Essential to the Tumor-Promoting Role of TGF-β.
Tripathi V; Sixt KM; Gao S; Xu X; Huang J; Weigert R; Zhou M; Zhang YE
Mol Cell; 2016 Nov; 64(3):549-564. PubMed ID: 27746021
[TBL] [Abstract][Full Text] [Related]
4. Emerging Multi-cancer Regulatory Role of ESRP1: Orchestration of Alternative Splicing to Control EMT.
Vadlamudi Y; Dey DK; Kang SC
Curr Cancer Drug Targets; 2020; 20(9):654-665. PubMed ID: 32564755
[TBL] [Abstract][Full Text] [Related]
5. Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer.
Fici P; Gallerani G; Morel AP; Mercatali L; Ibrahim T; Scarpi E; Amadori D; Puisieux A; Rigaud M; Fabbri F
Oncotarget; 2017 Jan; 8(2):2423-2436. PubMed ID: 27911856
[TBL] [Abstract][Full Text] [Related]
6. The RNA-binding protein Rbfox2: an essential regulator of EMT-driven alternative splicing and a mediator of cellular invasion.
Braeutigam C; Rago L; Rolke A; Waldmeier L; Christofori G; Winter J
Oncogene; 2014 Feb; 33(9):1082-92. PubMed ID: 23435423
[TBL] [Abstract][Full Text] [Related]
7. Emerging Mechanisms by which EMT Programs Control Stemness.
Wilson MM; Weinberg RA; Lees JA; Guen VJ
Trends Cancer; 2020 Sep; 6(9):775-780. PubMed ID: 32312682
[TBL] [Abstract][Full Text] [Related]
8. EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression.
Pradella D; Naro C; Sette C; Ghigna C
Mol Cancer; 2017 Jan; 16(1):8. PubMed ID: 28137272
[TBL] [Abstract][Full Text] [Related]
9. EHMT1/EHMT2 in EMT, cancer stemness and drug resistance: emerging evidence and mechanisms.
Nachiyappan A; Gupta N; Taneja R
FEBS J; 2022 Mar; 289(5):1329-1351. PubMed ID: 34954891
[TBL] [Abstract][Full Text] [Related]
10. SOX4: Joining the Master Regulators of Epithelial-to-Mesenchymal Transition?
Lourenço AR; Coffer PJ
Trends Cancer; 2017 Aug; 3(8):571-582. PubMed ID: 28780934
[TBL] [Abstract][Full Text] [Related]
11. Snail Driving Alternative Splicing of CD44 by ESRP1 Enhances Invasion and Migration in Epithelial Ovarian Cancer.
Chen L; Yao Y; Sun L; Zhou J; Miao M; Luo S; Deng G; Li J; Wang J; Tang J
Cell Physiol Biochem; 2017; 43(6):2489-2504. PubMed ID: 29131012
[TBL] [Abstract][Full Text] [Related]
12. HNRNPLL, a newly identified colorectal cancer metastasis suppressor, modulates alternative splicing of
Sakuma K; Sasaki E; Kimura K; Komori K; Shimizu Y; Yatabe Y; Aoki M
Gut; 2018 Jun; 67(6):1103-1111. PubMed ID: 28360095
[TBL] [Abstract][Full Text] [Related]
13. Snail represses the splicing regulator epithelial splicing regulatory protein 1 to promote epithelial-mesenchymal transition.
Reinke LM; Xu Y; Cheng C
J Biol Chem; 2012 Oct; 287(43):36435-42. PubMed ID: 22961986
[TBL] [Abstract][Full Text] [Related]
14. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
[TBL] [Abstract][Full Text] [Related]
15. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype.
Shapiro IM; Cheng AW; Flytzanis NC; Balsamo M; Condeelis JS; Oktay MH; Burge CB; Gertler FB
PLoS Genet; 2011 Aug; 7(8):e1002218. PubMed ID: 21876675
[TBL] [Abstract][Full Text] [Related]
16. TGF-β drives epithelial-mesenchymal transition through δEF1-mediated downregulation of ESRP.
Horiguchi K; Sakamoto K; Koinuma D; Semba K; Inoue A; Inoue S; Fujii H; Yamaguchi A; Miyazawa K; Miyazono K; Saitoh M
Oncogene; 2012 Jun; 31(26):3190-201. PubMed ID: 22037216
[TBL] [Abstract][Full Text] [Related]
17. Alternative microexon splicing by RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer.
Mochizuki Y; Funayama R; Shirota M; Kikukawa Y; Ohira M; Karasawa H; Kobayashi M; Ohnuma S; Unno M; Nakayama K
Int J Cancer; 2021 Nov; 149(10):1787-1800. PubMed ID: 34346508
[TBL] [Abstract][Full Text] [Related]
18. Noncoding RNAs in Cancer Cell Plasticity.
Xu J; Liu S
Adv Exp Med Biol; 2016; 927():173-89. PubMed ID: 27376735
[TBL] [Abstract][Full Text] [Related]
19. TGF-β regulates isoform switching of FGF receptors and epithelial-mesenchymal transition.
Shirakihara T; Horiguchi K; Miyazawa K; Ehata S; Shibata T; Morita I; Miyazono K; Saitoh M
EMBO J; 2011 Feb; 30(4):783-95. PubMed ID: 21224849
[TBL] [Abstract][Full Text] [Related]
20. The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer.
Suresh R; Ali S; Ahmad A; Philip PA; Sarkar FH
Adv Exp Med Biol; 2016; 890():57-74. PubMed ID: 26703799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
